title: [Intermittent intravenous high-dose cyclophosphamide therapy for advanced prostatic cancer with distant metastasis].
abstract: Twelve patients with advanced carcinoma of the prostate were treated with intravenous high-dose cyclophosphamide. All were hormone-resistant cases. At an interval of 3-4 weeks, cyclophosphamide was administered intravenously. The standard dosage of cyclophosphamide was 1,000 mg/m2 and a 10% lower dose was administered to patients with liver dysfunction, anemia and elderly patients. The results of 10 patients were evaluable. One case showed objective partial response, 1 case was stable and 8 patients showed objective progression according to the NPCP efficacy evaluation standard. The overall response rate was 20%, which we did not consider satisfactory. As to toxicity of cyclophosphamide, one patient died of severe acute hepatic failure, but in others, complications were mild to tolerable.
authors.affiliation: Department of Urology, Minoo City Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Kyakuno
authors.forename: S
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: K
authors.initials: K
authors.lastname: Matsumiya
authors.forename: M
authors.initials: M
authors.lastname: Osafune
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D003520:Cyclophosphamide